Abstracts Archive - Page 2115 of 2425 - ACR Meeting Abstracts

Abstract Number: 2068 • 2013 ACR/ARHP Annual Meeting
Comparison Of Radioimmunoprecipitation Versus Antigen Specific Assays For Identification Of Myositis Specific Autoantibodies In Dermatomyositis Patients
Eun Ha Kang¹, Eun Young Lee², Yun Jong Lee³, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ⁴Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: To confirm the antigen specificities of autoantibodies that precipitate 140 kDa (anti-p140) or 155/140 kDa polypeptides (anti-p155/140) on radioimmunoprecipitation (RIP) in Korean patients with…
Abstract Number: 2029 • 2013 ACR/ARHP Annual Meeting
Exposure-Response Modeling Of Canakinumab In The Avoidance Of Flares In Children With Systemic Juvenile Idiopathic Arthritis
Yuan Xiong¹, Wenping Wang¹, William Ebling¹, Haiying Sun¹, Olivier Luttringer², Ken Abrams¹, Nicola Ruperto³ and Hermine Brunner⁴, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Novartis Pharma AG, Basel, Switzerland, ³Istituto Gaslini, Genova, Italy, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Canakinumab (CAN), a fully human selective anti-IL-1β monoclonal antibody, has been shown to be efficacious in systemic juvenile idiopathic arthritis (SJIA), resulting in significantly…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 2031 • 2013 ACR/ARHP Annual Meeting
GRAID – Interim Analysis Of The Retrospective German Register In Autoimmune Diseases
Thomas Dörner¹, Enno Schmidt², Christoph Fiehn³, Frank Behrens⁴, Rebecca Fischer-Betz⁵, Martin Fleck⁶, Julia Holle⁷, Joerg C. Henes⁸, Annett M. Jacobi⁹, Christian Kneitz¹⁰, Esther Wittenborn¹¹, Fabian Proft¹², Hendrik Schulze-Koops¹³ and Christof Iking-Konert¹⁴, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, University of Lübeck, Lübeck, Germany, ³ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ⁴CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ⁵Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany, ⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ⁷Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ⁹Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, ¹⁰Internal Medicine II, Hospital Südstadt, Rostock, Germany, ¹¹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ¹³Division of Rheumatology, University of Munich, Munich, Germany, ¹⁴Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: Autoimmune diseases are characterized by high morbidity and lead frequently to physical disability and loss of income. They are the third most important disease…
Abstract Number: 2032 • 2013 ACR/ARHP Annual Meeting
How Does Age At Onset Influence Autoimmune Rheumatic Diseases?
Jenny Amaya-Amaya¹, Juan-Camilo Sarmiento-Monroy², Nicolás Molano-González¹, Mónica Rodríguez-Jiménez¹, Rubén-Darío Mantilla², Adriana Rojas-Villarraga¹ and Juan-Manuel Anaya², ¹Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ²School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia
Background/Purpose: Age at onset of disease (AOD) refers to the time period at which a patient experiences the first sign (s) and symptom(s). AOD varies…
Abstract Number: 2033 • 2013 ACR/ARHP Annual Meeting
Mortality Prognostic Factors Of Patients With Systemic Autoimmune Diseases Admitted To An Intensive Care Unit
Pamela Inés Doti¹, Sara Fernandez², Emmanuel Coloma³, Ona Escoda³, Ignasi Rodiguez-Pintó³, Pedro Castro², Gerard Espinosa³ and José María Nicolás², ¹Department of Autoimmune Diseases, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ²Medical Intensive Care Unit, Hospital Clínic, Barcelona, Barcelona, Spain, ³Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: To identify mortality prognostic factors of patients with systemic autoimmune diseases (SAD) admitted in a medical intensive care unit (ICU). Methods: Retrospective observational study…
Abstract Number: 2034 • 2013 ACR/ARHP Annual Meeting
Does Mixed Connective Tissue Disease Or Sharp’s Syndrome Really Exist?
Anne Barbarini¹, Christelle Sordet¹, Emmanuel Chatelus¹, Rose-Marie Javier¹, Joelle Goetz², Francois Lefebvre³, Jacques-Eric Gottenberg⁴, Thierry Martin⁵ and Jean Sibilia⁴, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Strasbourg University Hospital, strasbourg, France, ⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁵Strasbourg University Hospital, Strasbourg, France
Background/Purpose: The existence of Mixed Connective Tissue Disease (MCTD) has often been discussed in literature and its diagnostic criteria are very heterogeneous. Anti-U1-RNP antibodies are…
Abstract Number: 2035 • 2013 ACR/ARHP Annual Meeting
Description Of 142 Cases Of Relapsing Polychondritis Followed In a Single Center Since 2000
Jeremie Dion^1,2, Nathalie Costedoat-Chalumeau³, Damien Sene⁴, Judith Cohen-Bittan⁵, Gaëlle Leroux⁶, Camille Francès⁷ and Jean-Charles Piette⁸, ¹Faculté paris 7 Denis-Diderot, Paris, France, ²Internal medecine, Hopital Cochin, Paris, France, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴Internal Medicine, Hopital Lariboisière, Paris, France, ⁵Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ⁶Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ⁷Service de Dermatologie, Hopital Tenon, Paris, France, ⁸Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: Relapsing polychondritis (RP) is a rare condition characterized by recurrent inflammation of cartilaginous tissues and systemic manifestations. Data on prognosis available from the latest…
Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Mattia Baldini¹, Patrizia Aiello¹, Mirta Tiraboschi¹, Maria Grazia Sabbadini² and Elena Baldissera¹, ¹Internal Medicine and Clinical Immunology, Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy, ²Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…
Abstract Number: 2037 • 2013 ACR/ARHP Annual Meeting
Isolated Anti-Ro52 Antibody – Significance and Clinical Association
Yogesh Singh¹, Pravin Patil², Hilary Longhurst³, Garry Clarke³ and Bhaskar Dasgupta⁴, ¹Rheumatology, Southend university hospital, Westcliff-on-sea, United Kingdom, ²Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ³Immunology, Southend University Hospital, Westcliff on sea, United Kingdom, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Isolated anti-Ro52 antibody – significance and clinical association Background/Purpose: Antibodies against Ro-52 (TRIM21) have been described in patients with a broad spectrum of autoimmune diseases. Anti-Ro52…
Abstract Number: 2038 • 2013 ACR/ARHP Annual Meeting
Congenital Heart Block Related With Maternal Autoimmune Diseases: Descriptive Analysis Of a Series Of 17 Cases
Pamela Inés Doti¹, Ona Escoda², Sergi Cesar-Diaz³, Narcís Masoller⁴, Irene Teixidó⁴, Josep Maria Martinez⁴, Georgia Sarquella-Brugada⁵ and Gerard Espinosa², ¹Department of Autoimmune Diseases, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ²Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Spain, ³Arrhythmia Unit, Cardiology Section, Arrhythmia Unit, Cardiology Section, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain, ⁴Maternal Fetal Medicine Department, Hospital Clínic, Bacelona, Barcelona, Spain, ⁵Arrhythmia Unit, Cardiology Section, Hospital Sant Joan de Déu, Barcelona, Barcelona, Spain
Background/Purpose: To describe the clinical characteristics of maternal autoimmune-mediated fetal congenital heart block (CHB) in a cohort of pregnant women from an Autoimmune Diseases Pregnancy…
Abstract Number: 2039 • 2013 ACR/ARHP Annual Meeting
Micro and Nanoparticles As Possible Causative-Prognostic Co-Factors Of Mixed Cryoglobulinemia Syndrome
Erica Artoni¹, Gian Luca Sighinolfi¹, Daniele Campioli², Marco Sebastiani³, Dilia Giuggioli³ and Clodoveo Ferri⁴, ¹Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Laboratory of Clinical Chemistry, Azienda Ospedaliera - Policlino di Modena, Modena, Italy, ³Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy
Background/Purpose: We previously demonstrated that patients affected by membranoproliferative glomerulonephritis and mixed cryoglobulinemia syndrome (MCs) show the presence of circulating micro and nanoparticles (MPs and…
Abstract Number: 2040 • 2013 ACR/ARHP Annual Meeting
Pilot Study Of Abatacept In Patients With Refractory Autoimmune Chronic Urticaria
Clifton O. Bingham III¹, Marilyn Towns¹ and Susan J. Bartlett², ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Associations between chronic urticaria (CU) with autoantibodies and other autoimmune conditions have implicated T cells in CU initiation and/or propagation. Many patients (pts) have…
Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Amy G. Lau¹, Michael Clark¹, Diane D. Harrison¹, Anja Geldhof², Riikka Nissinen² and Marilyn Sanders¹, ¹Janssen Research & Development, LLC., Horsham, PA, ²Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].